352 related articles for article (PubMed ID: 23225450)
1. Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy.
Gigante M; Li G; Ferlay C; Perol D; Blanc E; Paul S; Zhao A; Tostain J; Escudier B; Negrier S; Genin C
Anticancer Res; 2012 Dec; 32(12):5447-51. PubMed ID: 23225450
[TBL] [Abstract][Full Text] [Related]
2. Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer.
Stewart GD; O'Mahony FC; Laird A; Rashid S; Martin SA; Eory L; Lubbock AL; Nanda J; O'Donnell M; Mackay A; Mullen P; McNeill SA; Riddick AC; Aitchison M; Berney D; Bex A; Overton IM; Harrison DJ; Powles T
Eur Urol; 2014 Nov; 66(5):956-63. PubMed ID: 24821582
[TBL] [Abstract][Full Text] [Related]
3. Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer.
Li G; Feng G; Gentil-Perret A; Genin C; Tostain J
J Urol; 2008 Aug; 180(2):510-3; discussion 513-4. PubMed ID: 18550116
[TBL] [Abstract][Full Text] [Related]
4. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.
Négrier S; Gravis G; Pérol D; Chevreau C; Delva R; Bay JO; Blanc E; Ferlay C; Geoffrois L; Rolland F; Legouffe E; Sevin E; Laguerre B; Escudier B
Lancet Oncol; 2011 Jul; 12(7):673-80. PubMed ID: 21664867
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
Rini BI; Bellmunt J; Clancy J; Wang K; Niethammer AG; Hariharan S; Escudier B
J Clin Oncol; 2014 Mar; 32(8):752-9. PubMed ID: 24297945
[TBL] [Abstract][Full Text] [Related]
6. CA9 as a molecular marker for differential diagnosis of cystic renal tumors.
Li G; Bilal I; Gentil-Perret A; Feng G; Zhao A; Peoc'h M; Genin C; Tostain J; Gigante M
Urol Oncol; 2012; 30(4):463-8. PubMed ID: 20822935
[TBL] [Abstract][Full Text] [Related]
7. Soluble carbonic anhydrase IX is not an independent prognostic factor in human renal cell carcinoma.
Papworth K; Sandlund J; Grankvist K; Ljungberg B; Rasmuson T
Anticancer Res; 2010 Jul; 30(7):2953-7. PubMed ID: 20683038
[TBL] [Abstract][Full Text] [Related]
8. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Choueiri TK; Regan MM; Rosenberg JE; Oh WK; Clement J; Amato AM; McDermott D; Cho DC; Atkins MB; Signoretti S
BJU Int; 2010 Sep; 106(6):772-8. PubMed ID: 20230385
[TBL] [Abstract][Full Text] [Related]
9. Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
Levy A; Menard J; Albiges L; Loriot Y; Di Palma M; Fizazi K; Escudier B
Eur J Cancer; 2013 May; 49(8):1898-904. PubMed ID: 23490648
[TBL] [Abstract][Full Text] [Related]
10. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
Bui MH; Seligson D; Han KR; Pantuck AJ; Dorey FJ; Huang Y; Horvath S; Leibovich BC; Chopra S; Liao SY; Stanbridge E; Lerman MI; Palotie A; Figlin RA; Belldegrun AS
Clin Cancer Res; 2003 Feb; 9(2):802-11. PubMed ID: 12576453
[TBL] [Abstract][Full Text] [Related]
11. Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials.
Zhou GX; Ireland J; Rayman P; Finke J; Zhou M
Urology; 2010 Feb; 75(2):257-61. PubMed ID: 19963243
[TBL] [Abstract][Full Text] [Related]
12. A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma.
Jobard E; Blanc E; Négrier S; Escudier B; Gravis G; Chevreau C; Elena-Herrmann B; Trédan O
Br J Cancer; 2015 Oct; 113(8):1148-57. PubMed ID: 26372698
[TBL] [Abstract][Full Text] [Related]
13. Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.
Schmidinger M; Zielinski CC
Cancer Treat Rev; 2009 May; 35(3):289-96. PubMed ID: 19232474
[TBL] [Abstract][Full Text] [Related]
14. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
Tsimafeyeu I; Zart JS; Chung B
BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
[TBL] [Abstract][Full Text] [Related]
15. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
[TBL] [Abstract][Full Text] [Related]
16. CA9 gene expression in conventional renal cell carcinoma: a potential marker for prediction of early metastasis after nephrectomy.
Li G; Feng G; Gentil-Perret A; Genin C; Tostain J
Clin Exp Metastasis; 2007; 24(3):149-55. PubMed ID: 17390110
[TBL] [Abstract][Full Text] [Related]
17. Tolerability of first-line therapy for metastatic renal cell carcinoma.
Porta C; Szczylik C
Cancer Treat Rev; 2009 May; 35(3):297-307. PubMed ID: 19249157
[TBL] [Abstract][Full Text] [Related]
18. CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis.
de Martino M; Klatte T; Seligson DB; LaRochelle J; Shuch B; Caliliw R; Li Z; Kabbinavar FF; Pantuck AJ; Belldegrun AS
J Urol; 2009 Aug; 182(2):728-34. PubMed ID: 19539328
[TBL] [Abstract][Full Text] [Related]
19. A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.
Stubbs C; Bardoli AD; Afshar M; Pirrie S; Miscoria M; Wheeley I; Porfiri E
Anticancer Res; 2017 Jan; 37(1):253-259. PubMed ID: 28011500
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of the management of metastatic renal cell carcinoma in the era of targeted therapies. retrospective clinical study over six years].
Latteux G; Lebdai S; Hoarau N; Abadie-Lacourtoisie S; Delva R; Chautard D; Azzouzi AR; Bigot P
Prog Urol; 2013 Mar; 23(3):184-94. PubMed ID: 23446283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]